leadf
logo-loader
viewSareum Holdings PLC

Cancer drug payment nudges Sareum Holdings into maiden profit

Tim Mitchell, chief executive of Sareum Holdings Plc (LON:SAR) tells Proactive the company's posted a maiden profit after receiving the first payments from licensing lead product, a Chk1 inhibitor cancer candidate, to Sierra Oncology.

Quick facts: Sareum Holdings PLC

Price: 1.55 GBX

AIM:SAR
Market: AIM
Market Cap: £50.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read